Topical Tranexamic Acid After Intravitreal Injections

Rambam Health Care Campus100 enrolled

Overview

We aim to investigate whether topical administration of Tranexamic acid can reduce the occurence of subconjunctival hemorrahge after routine intravitreal injections for retinal conditions.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

100

Conditions

Subconjunctival Hemorrhage

Interventions

Tranexamic acidDRUG

A single drop administered topically

Balanced Salt SolutionOTHER

A single drop administered topically

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Subjects receiving intravitreal injections as part of their routine ophthalmological care Exclusion Criteria: Pregnancy, Oral contraceptives/HRT use, Known systemic autoimmune disease, Renal failure, active/suspected infection or inflammation in the treated eye, subconjunctival hemorrahge prior to inclusion, History of subarachnoid hemorrahge, thromboembolic events, increased risk for thromboembolic events, known sensitivity to the study drug

Outcomes

Primary Outcomes

Subconjunctival hemorrahge

Time frame: 3 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.